Interim Unaudited Financial Statements

For the six months ended 30 September 2016

Table of contents

	Page
Consolidated statement of profit or loss and other comprehensive income	1
Consolidated statement of financial position	2
Consolidated statement of changes in equity	3
Consolidated statement of cash flows	4
Notes to the financial statements	5

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

		Unaudited for the six months ended 30 September 2016	Unaudited for the six months ended 30 September 2015	Audited for the year ended 31 March 2016
	Note	\$	\$	\$
Revenue from the sale of goods		361,443	305,882	472,104
Other income	3	461,707	861,358	1,370,317
Changes in inventories		209,121	(26,622)	(48,405)
Purchases of inventory		(459,448)	(102,973)	(204,530)
Employee benefit expenses and directors' fees		(576,427)	(444,839)	(946,914)
Administration		(152,739)	(169,687)	(365,721)
Research expenses	3	(564,377)	(131,104)	(171,959)
Stock for demonstration		-	-	(292,493)
Rent		(47,907)	(49,029)	(97,826)
Travel		(75,931)	(71,363)	(127,883)
Marketing & product approvals		(146,092)	(174,250)	(291,164)
Insurance		(37,724)	(41,706)	(74,106)
Shareholder relations & services		(11,196)	(65,967)	(93,309)
Foreign exchange loss	3	(381,432)	-	-
Amortisation & depreciation	3	(263,131)	(216,620)	(400,800)
Finance costs			(25,148)	(24,240)
Loss before income tax		(1,684,133)	(352,068)	(1,296,929)
Income tax expense				
Loss for the period		(1,684,133)	(352,068)	(1,296,929)
Other comprehensive income				
Item that may be reclassified subsequently to profit or loss				
Exchange differences on translating foreign subsidiary operations		(369,400)	566,734	640,217
Other comprehensive (loss) / income for the period		(369,400)	566,734	640,217
Total comprehensive (loss) / income for the period		(2,053,533)	214,666	(656,712)
Basic (losses) / earnings (cents per share)		(1.0)	(0.2)	(0.8)
Diluted (losses) / earnings (cents per share)		(1.0)	(0.2)	(0.8)

The accompanying notes form part of these interim financial statements.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2016

		Unaudited	Unaudited	Audited
		30 September 2016	30 September 2015	31 March 2016
	Note	\$	\$	\$
CURRENT ASSETS				
Cash and cash equivalents		1,410,327	3,704,736	2,304,698
Trade receivables		372,879	1,114,119	386,052
Other receivables		448,246	588,164	1,170,737
Goods and services taxes recoverable		72,059	98,947	62,606
Inventories		267,704	80,366	58,582
Other assets – prepayments		220,701	143,023	166,557
TOTAL CURRENT ASSETS		2,791,916	5,729,355	4,149,232
NON-CURRENT ASSETS				
Plant and equipment		10,510	11,327	6,951
Intangible assets		9,583,430	9,802,302	10,419,664
TOTAL NON-CURRENT ASSETS		9,593,940	9,813,629	10,426,615
TOTAL ASSETS		12,385,856	15,542,984	14,575,847
CURRENT LIABILITIES				
Trade and other payables		198,440	472,282	352,447
Employee benefits		80,142	52,177	76,987
TOTAL CURRENT LIABILITIES		278,582	524,459	429,434
NET ASSETS		12,107,274	15,018,525	14,146,413
EQUITY				
Issued capital	6	17,840,460	17,853,557	17,840,460
Share Option Reserve		187,106	160,349	172,712
Foreign currency translation reserve		(666,976)	(371,059)	(297,576)
Accumulated losses		(5,253,316)	(2,624,322)	(3,569,183)
Total Equity		12,107,274	15,018,525	14,146,413

TRUSCREEN LIMITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

		Share Capital	Accumulated Losses	Foreign Currency Translation Reserve	Option Reserve	Total
	Note	\$	\$	\$	\$	\$
Balance at 31 March 2015 Loss for the period to 30		12,921,275	(2,272,254)	(937,793)	145,955	9,857,183
September 2015 Other comprehensive income for the period		-	(352,068)	566,734		(352,068) 566,734
Total comprehensive income / (loss) for the period	_	-	(352,068)	566,734	-	214,666
Transactions with owners						
Issue of ordinary shares	6	4,932,282	-	-	-	4,932,282
Share based payment	· -				14,394	14,394
Total transactions with owners	-	4,932,282			14,394	4,946,676
Balance at 30 September 2015 (Unaudited)	=	17,853,557	(2,624,322)	(371,059)	160,349	15,018,525
Balance at 31 March 2016 (Audited) Loss for the period ended 30		17,840,460	(3,569,183)	(297,576)	172,712	14,146,413
September 2016 Other comprehensive (loss) /		-	(1,684,133)		-	(1,684,133)
income for the period	-			(369,400)		(369,400)
Total comprehensive income / (loss) for the period		-	(1,684,133)	(369,400)	-	(2,053,533)
Transactions with owners	-					
Share based payment	-				14,394	14,394
Total transactions with owners		-	-	-	14,394	14,394
Balance at 30 September 2016 (Unaudited)	<u>-</u>	17,840,460	(5,253,316)	(666,976)	187,106	12,107,274

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

		Unaudited for the six months ended 30 September 2016	Unaudited for the six months ended 30 September 2015	Audited for the year ended 31 March 2016
	Note	\$	\$	\$
CASH FLOW FROM OPERATING ACTIVITIES				
Cash receipts from customers		374,616	1,324,142	1,050,083
Cash paid to suppliers and employees		(2,305,914)	(1,697,866)	(2,386,515)
Cash received from 45% refundable tax offset		1,172,039	-	679,855
Interest paid		-	(25,148)	(24,240)
Interest received		12,159	10,348	18,713
Net cash provided by / (used in) operating activities	7	(747,100)	(388,524)	(662,104)
CASH FLOW FROM INVESTING ACTIVITIES				
Development of intangible asset – development costs of upgraded cervical cancer console		(141,188)	(957,080)	(2,071,893)
Purchase of plant and equipment		(6,083)	-	(6,975)
Net cash used in investing activities		(147,271)	(957,080)	(2,078,868)
CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of shares	6	-	5,080,000	5,080,000
(Repayment) / Proceeds of borrowing		-	(439,920)	(407,800)
Share issue costs		-	(147,718)	(160,815)
Net cash provided by / (used in) financing activities		-	4,492,362	4,511,385
Net (decrease) / increase in cash and cash equivalents		(894,371)	3,146,758	1,770,413
Cash and cash equivalents at beginning of period		2,304,698	534,285	534,285
Effects of exchange rate changes on cash and cash equivalents		-	23,693	-
Cash and cash equivalents at end of period		1,410,327	3,704,736	2,304,698

NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

1. REPORTING ENTITY

Truscreen Limited (the "Company") is a Tier 1 for-profit listed incorporated public company and is an issuer on the New Zealand Stock Exchange Alternative Market ("NZAX"). The Company is a limited liability company incorporated and domiciled in New Zealand and registered under the Companies Act 1993.

Truscreen is a FMC reporting entity for the purposes of the Financial Reporting Act 2013 and the Financial Markets Conduct Act 2013.

The Group's principal activity relates to the development and manufacture of cancer detection devices and systems.

The consolidated interim financial statements presented for the six months ended 30 September 2016 are those of Truscreen Limited and its subsidiaries (the "Group"). References to "Truscreen" are used to refer both to the Group and Truscreen Limited (the "Company").

These interim financial statements were authorised for issue by the Board of Directors on the 12 December 2016.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PREPARATION

These financial statements are unaudited and have been prepared in accordance with New Zealand Generally Accepted Accounting Practice ("NZ GAAP") and are in compliance with NZIAS 34: Interim Financial Reporting.

The consolidated interim financial statements have been prepared in New Zealand dollars, which is the functional currency. These financial statements do not include all the information required for full financial statements and consequently should be read in conjunction with the Group's financial statements for the year ended 31 March 2016.

The same accounting policies have been followed in these financial statements as were applied in the preparation of the Group's audited financial statements for the year ended 31 March 2016.

CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

When preparing the interim financial statements, management is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on experience and other factors that are believed to be reasonable under the circumstances. Actual results may differ from the estimates, judgements and assumptions made by management. Estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected. Information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements can be found in the previous annual report.

SEASONALITY

Operations are not subject to seasonal influences.

NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

3. SIGNIFICANT TRANSACTIONS AFFECTING NET PROFIT / (LOSS)

Significant transactions affecting net profit / loss

The following significant items affecting the loss for the period are highlighted below because of their size:

	Unaudited for the six months ended 30 September 2016	Unaudited for the six months ended 30 September 2015	Audited for the year ended 31 March 2016
	\$	\$	\$
Other income			
Research and development grant	449,548	595,262	1,170,737
Foreign exchange gain / unrealised	-	255,748	180,867
Expense			
Amortisation of intangible assets	260,961	212,868	392,176
Foreign exchange loss / unrealised	381,432	-	-
Research & development costs	564,377	131,104	171,959

Research & development costs increased in the six months ended 30 September 2016 compared to the six months ended 30 September 2015 largely due to:

- Further work on developing and testing the algorithm;
- Software & firmware improvements incorporated from feedback on prototypes;
- Ongoing regulatory and verification processes; and
- Changes and improvements to the Ultra console following beta testing.

Amortisation of intangibles commenced on 1 February 2015 and 1 April 2016 as the product to which the particular intangibles related to became available for use. Accordingly, amortisation expense was more significant in the current period than in prior periods.

4. ADMINSTRATIVE AND OTHER OPERATING EXPENSES

Administrative expenses increased in the six months ended 30 September 2016 compared to the six months ended 30 September 2015 largely due to costs associated with compliance, marketing and travel necessary for expansion and ongoing operations in various regions including China, Mexico and Europe.

NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

5. OPERATING SEGMENTS

The Group operates in one operating segment. It owns the rights to the Truscreen Cervical Cancer Screening System. The system comprises a medical device and process designed to detect the presence in real time of precancerous and cancerous tissue on the cervix.

The Group is in the process of obtaining further regulatory approvals. On the granting of these approvals the Group anticipates the ability to increase distribution and revenue. It is anticipated revenues will be obtained largely from Asia, Europe, Central and South America. The limited revenues to date have been obtained in anticipation of these approvals. These revenues have been obtained from distributors.

Two major customers each contributed more than 10% of the Group's revenue in the six months to 30 September 2016 (2015: three customers):

- One customer provided revenue of \$147,111 (41%);
- One customer provided revenue of \$75,886 (21%);

No additional disclosure is required in the interim financial statements as the Group has one reportable segment.

6. SHARE CAPITAL

	No.	\$
Balance as at 31 March 2015	144,446,666	12,921,275
Private share placement	13,080,000	3,270,000
Share purchase plan	7,240,000	1,810,000
Share issue costs		(147,718)
Balance as at 30 September 2015	164,766,666	17,853,557
Balance as at 31 March 2016	164,766,666	17,840,460
Private share placement	-	-
Share purchase plan	-	-
Share issue costs		
Balance as at 30 September 2016	164,766,666	17,840,460

TRUSCREEN LIMITED NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

7. RECONCILIATION OF CASH FLOW FROM OPERATING ACTIVITIES

	Unaudited for the six months ended 30 September 2016	Unaudited for the six months ended 30 September 2015	Audited for the year ended 31 March 2016
	\$	\$	\$
Reconciliation of cash flow from operations with loss after income tax			
(Loss) for the period	(1,684,133)	(352,068)	(1,296,929)
Adjusted for:			
Share based expense payment – employment expenses	14,394	14,394	26,757
Amortisation and depreciation	263,131	216,620	400,800
Assets written off	-	-	6,339
Exchange difference arising from translating loss items at the date of transaction and translating cash balances at year end rates	206,227	(47,694)	(72,152)
Operating cash flows before working capital changes	(1,200,381)	(168,748)	(935,185)
(Increase) / Decrease in trade receivables	13,173	405,251	870,470
(Increase) / Decrease in other receivables	722,491	(206,471)	(526,196)
(Increase) / Decrease in goods and services taxes recoverable	(9,453)	(64,971)	(28,630)
(Increase) / Decrease in prepayments	(54,144)	(143,023)	(166,557)
(Increase) / Decrease in inventory	(209,122)	14,492	35,465
Increase / (Decrease) in trade and other payables	(12,819)	(248,827)	39,946
Increase / (Decrease) in provisions	3,155	23,773	48,583
Net cash from operating activities	(747,100)	(388,524)	(662,104)

TRUSCREEN LIMITED NOTES TO THE INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016

8. NET TANGIBLE ASSETS PER SHARE

	Unaudited 30 September 2016	Unaudited 30 September 2015	Audited 31 March 2016
Net tangible assets	2,523,844	5,216,223	3,726,749
Shares on issue at the end of period	164,766,666	164,766,666	164,766,666
Net tangible assets per share (cents per share)	1.53	3.17	2.26

9. EVENTS SUBSEQUENT TO END OF THE INTERIM PERIOD

There have been no events since the end of the interim period which would have a material effect on the Group's interim financial statements for the 6 months ended 30 September 2016.